| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Mixed Poisson Regression Model for Analysis of Patent Data |
0 |
0 |
0 |
290 |
0 |
2 |
4 |
1,742 |
| Are All Patent Examiners Equal? The Impact of Examiner Characteristics |
0 |
0 |
0 |
366 |
0 |
2 |
6 |
2,009 |
| Balancing Incentives: The Tension Between Basic and Applied Research |
0 |
0 |
1 |
419 |
1 |
1 |
5 |
1,887 |
| Characteristics of Demand for Pharmaceutical Products: an Examination of four Cephalosporins |
0 |
0 |
0 |
0 |
2 |
2 |
6 |
2,375 |
| Deals Not Done: Sources of Failure in the Market for Ideas |
0 |
0 |
0 |
31 |
4 |
5 |
6 |
104 |
| Do Patents Matter?: Empirical Evidence after GATT |
0 |
0 |
0 |
297 |
2 |
2 |
2 |
821 |
| Entry and Patenting in the Software Industry |
0 |
0 |
1 |
191 |
2 |
3 |
8 |
646 |
| Faster, Smaller, Cheaper: An Hedonic Price Analysis of PDAs |
0 |
0 |
0 |
101 |
2 |
2 |
3 |
403 |
| Generics and New Goods in Pharmaceutical Price Indexes |
0 |
0 |
0 |
266 |
1 |
2 |
4 |
1,212 |
| Gone But Not Forgotten: Labor Flows, Knowledge Spillovers, and Enduring Social Capital |
0 |
0 |
0 |
269 |
2 |
4 |
9 |
844 |
| Hedonic Analysis of Arthritis Drugs |
0 |
0 |
0 |
163 |
2 |
2 |
4 |
1,019 |
| Industry Effects and Appropriability Measures in the Stock Markets Valuation of R&D and Patents |
0 |
0 |
3 |
390 |
3 |
3 |
8 |
1,170 |
| Is Distance from Innovation a Barrier to the Adoption of Artificial Intelligence? |
0 |
0 |
13 |
19 |
3 |
6 |
20 |
30 |
| Is Distance from Innovation a Barrier to the Adoption of Artificial Intelligence? |
0 |
0 |
6 |
23 |
1 |
1 |
21 |
46 |
| Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs |
0 |
0 |
0 |
157 |
0 |
0 |
3 |
1,636 |
| Is distance from innovation a barrier to the adoption of artificial intelligence |
3 |
4 |
8 |
24 |
3 |
6 |
21 |
40 |
| Is distance from innovation a barrier to the adoption of artificial intelligence |
0 |
1 |
19 |
19 |
2 |
4 |
35 |
35 |
| Market Conditions and Retirement of Physical Capital: Evidence fron Oil Tankers |
0 |
0 |
0 |
44 |
2 |
5 |
5 |
478 |
| Measuring competence?: exploring firm effects in pharmaceutical research |
1 |
1 |
1 |
511 |
3 |
3 |
8 |
1,346 |
| Not Invented Here? Innovation in Company Towns |
0 |
0 |
0 |
83 |
2 |
4 |
5 |
336 |
| Patent Thickets, Licensing and Innovative Performance |
0 |
0 |
1 |
130 |
1 |
2 |
6 |
417 |
| Patent thickets, licensing and innovative performance |
0 |
0 |
0 |
58 |
0 |
2 |
2 |
154 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
0 |
74 |
0 |
0 |
2 |
161 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
0 |
30 |
1 |
2 |
5 |
102 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
0 |
52 |
4 |
5 |
5 |
121 |
| Patents and the Survival of Internet-related IPOs |
0 |
0 |
0 |
84 |
4 |
8 |
8 |
301 |
| Patents and the global diffusion of new drugs |
0 |
0 |
1 |
20 |
0 |
3 |
4 |
91 |
| Patents and the global diffusion of new drugs |
0 |
0 |
0 |
54 |
2 |
2 |
2 |
88 |
| Patents, Thickets, and the Financing of Early-Stage Firms: Evidence from the Software Industry |
0 |
0 |
1 |
104 |
0 |
1 |
4 |
352 |
| Price Indexes for Clinical Trial Research: A Feasibility Study |
0 |
0 |
3 |
32 |
1 |
3 |
15 |
120 |
| Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research |
0 |
0 |
1 |
125 |
0 |
2 |
7 |
369 |
| Public-Private Interaction and the Productivity of Pharmaceutical Research |
0 |
0 |
1 |
189 |
1 |
3 |
7 |
767 |
| Racing or spilling?: the determinants of research productivity in ethical drug discovery |
0 |
0 |
0 |
53 |
1 |
2 |
3 |
190 |
| Racing to invest?: the dynamics of competition in ethical drug discovery |
0 |
0 |
1 |
297 |
1 |
2 |
5 |
603 |
| Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery |
0 |
0 |
0 |
1 |
2 |
3 |
7 |
501 |
| Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry |
0 |
0 |
2 |
362 |
9 |
9 |
18 |
1,093 |
| Scale, scope and spillovers: the determinants of research productivity in ethical drug discovery |
0 |
0 |
0 |
145 |
2 |
3 |
7 |
333 |
| The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research |
0 |
0 |
2 |
310 |
3 |
4 |
20 |
1,978 |
| The Impact of Artificial Intelligence on Innovation |
4 |
7 |
32 |
422 |
25 |
68 |
221 |
3,429 |
| The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity |
1 |
1 |
1 |
57 |
2 |
3 |
8 |
107 |
| University Research, Industrial R&D, and the Anchor Tenant Hypothesis |
0 |
0 |
1 |
229 |
1 |
1 |
6 |
951 |
| Why are Some Regions More Innovative than Others? The Role of Firm Size Diversity |
0 |
0 |
1 |
101 |
2 |
3 |
8 |
291 |
| Why are some regions more innovative than others? The role of firm size diversity |
0 |
0 |
0 |
87 |
1 |
2 |
2 |
91 |
| Total Working Papers |
9 |
14 |
100 |
6,679 |
100 |
192 |
555 |
30,789 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery |
0 |
2 |
8 |
29 |
1 |
5 |
40 |
102 |
| Access to intellectual property for innovation: Evidence on problems and coping strategies from German firms |
0 |
0 |
1 |
24 |
0 |
2 |
7 |
127 |
| Analysis of Patent Data--A Mixed-Poisson-Regression-Model Approach |
0 |
0 |
0 |
0 |
1 |
3 |
5 |
937 |
| Canada’s Patent Productivity Paradox: Recent Trends and Implications for Future Productivity Growth |
0 |
5 |
10 |
16 |
4 |
10 |
55 |
83 |
| Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins |
0 |
0 |
1 |
411 |
2 |
4 |
11 |
1,174 |
| Deals not done: Sources of failure in the market for ideas |
0 |
0 |
1 |
9 |
1 |
2 |
6 |
82 |
| Diffusion of New Drugs in the Post-TRIPS Era |
0 |
0 |
1 |
54 |
0 |
0 |
2 |
170 |
| Entry and Patenting in the Software Industry |
0 |
0 |
0 |
44 |
1 |
5 |
10 |
255 |
| Faster, smaller, cheaper: an hedonic price analysis of PDAs |
0 |
0 |
0 |
41 |
2 |
4 |
6 |
263 |
| Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy |
0 |
0 |
1 |
27 |
0 |
2 |
6 |
106 |
| Generics and New Goods in Pharmaceutical Price Indexes |
0 |
0 |
1 |
234 |
0 |
1 |
7 |
932 |
| Generics and New Goods in Pharmaceutical Price Indexes: Reply |
0 |
0 |
0 |
35 |
1 |
1 |
2 |
172 |
| Industry Effects and Appropriability Measures in the Stock Market's Valuation of R&D and Patents |
0 |
1 |
5 |
365 |
0 |
2 |
18 |
1,253 |
| Information Technology and Intangible Output: The Impact of IT Investment on Innovation Productivity |
0 |
1 |
6 |
46 |
3 |
5 |
19 |
156 |
| Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs |
0 |
0 |
0 |
29 |
0 |
2 |
4 |
392 |
| Measuring Competence? Exploring Firm Effects in Pharmaceutical Research |
0 |
1 |
2 |
19 |
5 |
7 |
27 |
142 |
| New Pills for Poor People? Empirical Evidence after GATT |
0 |
0 |
2 |
239 |
0 |
1 |
5 |
523 |
| Not Invented Here? Innovation in company towns |
0 |
0 |
0 |
51 |
2 |
2 |
9 |
369 |
| Opportunity costs and entrepreneurial activity |
0 |
1 |
1 |
159 |
1 |
3 |
7 |
477 |
| Patent thickets, licensing and innovative performance |
0 |
0 |
0 |
44 |
0 |
1 |
7 |
164 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
1 |
78 |
3 |
9 |
20 |
402 |
| Patents and the survival of Internet-related IPOs |
0 |
0 |
2 |
98 |
3 |
5 |
14 |
414 |
| Patents, Thickets and the Financing of Early‐Stage Firms: Evidence from the Software Industry |
0 |
0 |
4 |
80 |
1 |
4 |
17 |
357 |
| Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs |
0 |
0 |
0 |
0 |
0 |
3 |
6 |
23 |
| Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs |
0 |
0 |
0 |
5 |
1 |
4 |
12 |
44 |
| Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research |
0 |
0 |
0 |
15 |
2 |
3 |
9 |
105 |
| Racing To Invest? The Dynamics of Competition in Ethical Drug Discovery |
0 |
0 |
0 |
12 |
0 |
1 |
9 |
646 |
| Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research |
1 |
2 |
4 |
263 |
2 |
4 |
13 |
652 |
| Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery |
0 |
1 |
6 |
634 |
1 |
4 |
25 |
1,961 |
| The Economics of Reproducibility in Preclinical Research |
0 |
0 |
0 |
10 |
1 |
7 |
13 |
64 |
| The Global Location of Biopharmaceutical Knowledge Activity: New Findings, New Questions |
0 |
0 |
0 |
6 |
0 |
1 |
3 |
52 |
| The Impact of Incremental Innovation in Biopharmaceuticals |
0 |
0 |
1 |
18 |
3 |
4 |
8 |
72 |
| The anchor tenant hypothesis: exploring the role of large, local, R&D-intensive firms in regional innovation systems |
1 |
1 |
6 |
218 |
7 |
12 |
29 |
712 |
| Untangling the origins of competitive advantage |
1 |
2 |
4 |
10 |
1 |
4 |
7 |
38 |
| Why are some regions more innovative than others? The role of small firms in the presence of large labs |
0 |
1 |
1 |
81 |
0 |
3 |
13 |
334 |
| Total Journal Articles |
3 |
18 |
69 |
3,404 |
49 |
130 |
451 |
13,755 |
LogEc is hosted by the
Örebro University School of Business.